CONTEXT: Cognitive impairment (CI) affects approximately 45% of middle-aged and older adults with type 2 diabetes mellitus (T2DM) globally. Although formal comprehensive neuropsychological tests are the gold standard for diagnosing CI, they are often time-intensive and may not be feasible in primary care. OBJECTIVE: This study aimed to develop and validate a novel risk stratification score (RSS) to rapidly and comprehensively predict CI risk among middle-aged and older adults with T2DM, offering a streamlined alternative in clinical practice. METHODS: A cross-sectional study was conducted from July 2023 to February 2024 in a primary care polyclinic in Singapore's western region. Participants aged between 40 and 85 diagnosed with T2DM (n = 150) were included in a convenience sampling. The primary outcome was CI status, which was assessed using formal neuropsychological tests, including the Montreal Cognitive Assessment (MoCA). RESULTS: CI was identified in 49.3% of participants (n = 74). The RSS, incorporating the MoCA, diastolic blood pressure, and Short Physical Performance Battery, demonstrated excellent discrimination, achieving an area under the receiver operating characteristic curve of 0.802 (P < .001). With an optimal cutoff of 0.3, the model showed a sensitivity of 63.5% and specificity of 86.8%, effectively differentiating high- and low-risk CI groups. CONCLUSION: RSS in clinical practice, exemplified by the Integrated Metabolic Cognitive Risk Stratification Pathway, is a promising tool for rapid CI risk assessment in primary care. Its robust predictive accuracy and ease of use support its application for early intervention in middle-aged and older adults with T2DM. Future studies should validate its use longitudinally and across diverse populations to enhance generalizability.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: